Oncology

Overview

Radiopharmaceutical therapies represent an effective way to treat solid cancers by using tumor targeting small molecules, peptides or biologics to deliver a cytotoxic payload that induces DNA damage in tumor cells, while limiting damage to normal and healthy tissue.

Streamlined development, evaluation and clinical translation of radiopharmaceuticals requires a partner that has extensive scientific, regulatory and operational expertise. Working with a CRO that provides a complete solution ensures data is delivered in a timely manner to make a go/no-go decision on your imaging or
therapeutic candidates.

Services Include:

• Radiochemistry development – conjugation, radiolabeling, stability and immunoreactivity
• Preclinical proof-of-concept studies – biodistribution, efficacy, toxicology
• Investigational New Drug (IND)/Clinical Trial Application (CTA) submission support with clinical protocol development
• Single-site, first-in-human through multi-site, late phase clinical study support
• Good manufacturing practice (GMP) radiochemistry development and production support for imaging agents
• Preclinical and clinical dosimetry and advanced quantitative image analysis

Watch Theranostics Panel Discussion
Info Sheet – Radiopharmaceutical Therapy

Capabilities

Invicro is an industry-leading CRO providing full-service PSMA-PET solutions from radiochemistry development to preclinical and Phase 0-IV clinical trials. We support researchers that are developing PSMA-targeted prostate cancer therapeutics or multi-specifics, and groups using PSMA expression as a biomarker for patient selection, and treatment response in prostate cancer clinical trials. Invicro advances PSMA-PET standard of care by combining advanced image analytics and artificial intelligence with standard PET SUV readouts to ensure you are receiving the most meaningful data from your images. In recent years, Invicro has overseen more clinical PSMA-PET scans (>3,600) than most other imaging CROs and is one of the only organizations to support an FDA submission combining AI and quantitative PET.

Our full-service PSMA-PET solutions include:

• • Complete global core lab support for Phase 0-IV clinical trials
  • Radiology expertise for study design, image analysis and sub-specialty reads (PCWG3)
  • Advanced analytical tools for whole body image quantification to estimate disease burden, lesion localization, and response to therapy.
  • Radiochemistry development and expert guidance on PSMA ligand access and utilization, including external manufacturing support
  • Preclinical solutions for discovery research
  • Extensive experience with Regulatory filing support (e.g., IND-enabling support)

Invicro’s clinical team has expertise in medical imaging and a vast range of tools to support your cancer drug discovery and development needs. With over 200 scientists and 4,800+ qualified imaging centers and clinical sites across the globe, Invicro has the advanced scientific, medical and regulatory expertise and project management scale to deliver studies from Phase 0-IV. Our technology platforms support key decision-making in:

• First-in-human, single-site clinical trial support
• Late stage, global multi-center clinical trial support with response criteria reads
• Advanced image analytics including dosimetry
• Safety profile and therapeutic efficacy studies
• Study design and consultation
• Criteria-based centralized independent reviews and internal analysis

Our imaging core lab offers criteria-driven reads for standard-of-care projects and our state-of-the-art in-house software enables 3D region-of-interest generation to support quantitative analysis methods, such as PERCIST. We also partner with subspecialist independent readers that focus on specific areas of expertise. Some of the validated criteria examples include:

• RECIST 1.0/1.1
• PCWG 2.0/3.0
• RANO
• LUGANO
• IMWG
• CHESON
• iRECIST
• irRECIST
• LYRIC
• irRC

Learn More

Invicro’s medical image analysis team supports standard analysis of FDG PET imaging, including PERCIST and other SUV-based metrics, metabolic tumor volume and total lesion glycolysis. The image analysis team also specializes in developing and applying a broad range of tools to support advanced quantitative oncology tracer characterization and analytics across a broad range of modalities and studies. Some examples include:

• Powerful, multi-modal tumor and organ Segmentation tools
• A range of flexible Biomathematical Modeling tools
• Dosimetry calculations across radionuclide, administration route, and species
• Integrated Radiomics pipelines using standard and custom feature vectors
• Preclinical and clinical support for Tracer Characterization
• Sophisticated batch Image Triage and preprocessing methods

For more information, check out some of our most popular case studies. A full list is also available in our case studies section.

Dosimetry Analysis

Radiomics

Biodistribution

Multi-Modality – Oncology

Learn More

Invicro’s discovery and preclinical services team provides study design, study execution and data analysis services for a broad-range of solid and non-solid tumor studies. Our preclinical oncology team uses state-of-the-art imaging techniques to characterize the behavior of novel therapies, including antibodies, radioligand therapies, peptides, cell therapies (e.g., CAR-T), exosomes and other tumor-targeting modalities in diverse tumor model types (e.g., subcutaneous, orthotopic, metastatic). Non-clinical work supported by Invicro can be used to move into first-in-human studies to late-stage clinical multicenter trials. Our core capabilities include the measurement of multiple readouts, including:

• Biodistribution of test articles
• Target density/engagement
• Pharmacokinetics (PK)
• Pharmacodynamics (PD)
• Tumor growth properties
• Therapeutic efficacy
• Dosimetry

Learn More

Invicro’s radiochemistry team has experience with most commercially available radioisotopes used for PET/SPECT imaging and several used in targeted radiotherapy. Our capabilities span from first-in-human clinical studies to GMP implementation of novel radiotracers, including:

• A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of ¹⁸F-FB-A20FMDV2 for Imaging the Integrin αvβ
• Clinical Translation of a Click-Labeled ¹⁸F-Octreotate Radioligand for Imaging Neuroendocrine Tumors
• ¹⁸F-ICMT-11, a Caspase-3–Specific PET Tracer for Apoptosis: Biodistribution and Radiation Dosimetry
• Biodistribution and radiation dosimetry of deuterium-substituted ¹⁸F-fluoromethyl-[1, 2-2H4]choline in healthy volunteer

Learn More

Webinars

The Resurgence of Theranostics: Challenges and Successes of Clinical Application

Translating Radiolabeled Biologics – Strategies for Successful IND Submission

EXPLORER as a Transformational Imaging Technology for Drug Development

Segmentation of Lesions in Whole-Body PET/CT Using Deep Learning

Utilizing Imaging Agent Biomarkers for Improved Patient Management – Challenges and Successes

PSMA: Imaging Biomarker Development

The Changing Landscape of Response Assessment in Oncology

Optimization of a Novel Tissue Test to Visualize and Quantify Membrane PSMA Expression in Prostate Cancer

Imaging Biomarkers in Metastatic Prostate Cancer

View Additional Webinars

Case Studies

Radiolabeling of a DOTA Conjugate Antibody for Theranostic Applications

Preclinical development and first-in-human study of ⁶⁸Ga-MLN6907

Dosimetry Analysis

Biodistribution

CFT and Bioluminescence

Multi-Modality – Oncology

Clinical Tumor Sample

Antigen Density Estimation – Clinical PET/CT Protocol Design for a First-In-Human Diagnostic Peptide

Radiomics

Tumor Quantitation

View Additional Case Studies

Infographics

Radiopharmaceutical Drug Development
Complete Radiopharmaceutical Therapy Services